Document is current

Article History

Received: 24 September 2024

Accepted: 23 February 2025

First Online: 26 March 2025

Declarations

:

: Site-specific ethics at the University of Queensland for all translational biomarker work was covered by ethics approval 2015–12-817-PRE-6.

: Not applicable.

: OG reports honoraria from Genomic Health/Exact Sciences, Roche, Celgene, Pfizer, Novartis, NanoString Technologies, AstraZeneca; consulting or advisory role for Celgene, Genomic Health/Exact Sciences, Lilly, MSD, Novartis, Pfizer, Roche, Seagen, Pierre Fabre, Gilead, Molecular health; travel support from Roche; all outside of the submitted work; and co-director position at West German Study Group. UN reports honoraria from Agendia, Amgen, Celgene, Genomic Health, NanoString Technologies, Novartis Pharma, Pfizer Pharmaceuticals, Roche/Genentech, Teva; consulting or advisory role for Genomic Health, Roche, Seagen; research funding from Agendia (Inst), Amgen (Inst), Celgene (Inst), Genomic Health (Inst), NanoString Technologies (Inst), Roche (Inst), Sanofi (Inst); expert testimony for Genomic Health; travel support from Genomic Health, Pfizer Pharmaceuticals, Roche; all outside of the submitted work; and co-director position at West German Study Group. SK reports consulting or advisory role for Amgen, AstraZeneca, Celgene, Daiichi-Sankyo, Genomic Health/Exact Sciences, Lilly, Novartis, Seagen, Pfizer, pfm Medical, Roche, Somatex, Gilead, Roche, MSD Oncology, Sonoscape, Agendia; travel support from Roche, Daiichi Sankyo; research support from Roche, Novartis; fees for non-CME services from Somatex, Roche, Novartis, Lilly; ownership interests for West German Study Group; all outside of the submitted work; and co-director position at West German Study Group. HF reports honoraria from Roche, iOMEDICO; travel support from Celgene, Amgen; all outside of the submitted work. MB reports honoraria from AstraZeneca, Daiichi Sankyo, Exact Sciences, Lilly, Novartis, Pfizer, Roche, MSD; consulting or advisory role for AstraZeneca, Exact Sciences, Novartis, Puma, Roche, Gilead, Daiichi Sankyo, Lilly, Pfizer, Sirius Medical; and travel support from AstraZeneca, Daiichi Sankyo, Gilead, Medac, Novartis, Roche; all outside of the submitted work. CU reports honoraria from Medi-Semina GmbH, FomF GmbH, RG GmbH für Information, Organisation, Friesland Kliniken—St. Johannes Hospital; consulting or advisory role for Lilly GmbH, Pharma Mar GmbH; research funding from AstraZeneca GmbH, Novartis Pharma GmbH, GBG Forschungs GmbH, Heraclin GmbH, Pierre Fabre Pharma GmbH, Roche AG, Pfizer Pharma GmbH, Universitätsklinikum Ulm, Westdeutsche Studiengruppe GmbH, Alcedis GmbH, AGO Research GmbH, IOMEDICO AG, MMF GmbH; travel support from KelCon Congress & Conferences; speakers' bureau at Pfizer, Novartis, Roche, PharmaMar, AstraZeneca; all outside of the submitted work. BA reports honoraria from Pfizer, Roche Pharma, Merck Sharp & Dohme, onkowissen.de, Novartis Pharma, AstraZeneca, PharmaMar, Lilly, promedicis; all outside of the submitted work. RW reports consulting fees or advisory role, travel support, and speakers' bureau at Agendia, Amgen, Aristo, Astra Zeneca, Boehringer Ingelheim, Carl Zeiss, Celgene, Daiichi-Sankyo, Eisai, Exact Sciences, Genomic Health, Gilead, Glaxo Smith Kline, Hexal, Lilly, Medstrom Medical, MSD, Mundipharma, Mylan, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre, PumaBiotechnolgogy, Riemser, Roche, Sandoz/Hexal, Sanofi Genzyme, Seattle Genetics /Seagen, Tesaro Bio, Teva, Veracyte, Viatris; and other financial or non-financial interests from FomF (Forum for medical education in Germany), Aurikamed, Clinsol, Pomme Med; all outside of the submitted work. HHK reports honoraria and consulting or advisory role for Lilly, Roche Pharma, Exact Sciences, Astra Zeneca; all outside of the submitted work. MG reports consulting or advisory role for AstraZeneca; travel support from Daiichi Sankyo, AstraZeneca; all outside of the submitted work. NH reports consulting or advisory role for Daiichi Sankyo, Novartis, Pfizer, Roche, Sandoz, Seagen; minority ownership interests for West German Study Group; honoraria for lectures from AstraZeneca; Daiichi-Sankyo, Gilead, Novartis; Pfizer; Pierre Fabre; Roche; research funding from Lilly, MSD, Novartis, Pfizer, Roche/Genentech (all to institution); and co-director position at West German Study Group. All other authors declare no competing interests.